Covid-19 : roadmap to recovery.
by Wilmington Healthcare.
Series: Insights for industry ; August 2020.Publisher: Wilmington Healthcare, [Basildon]: 2020.Description: [50]p.Summary: The pandemic response in the UK has now moved on to ‘phase 3’, setting out a gradual return to pre-Covid NHS service levels. The NHS is drawing up a ‘roadmap’ to recovery, and likewise, industry is beginning to look to the future to see where it fits in. This white paper looks at the next stages in the recovery for the NHS, and explores the vital role industry has in supporting the health service. It covers three major areas: the NHS Reset initiative and its attendant policies; the status and aims of the various NHS stakeholders tasked with taking the service through the next phase; and the issues surrounding the recovery from the point of view of the life science industries..Subject(s): Covid-19 | NHS | future projections | commercial enterprises | viewsDigital copyAvailability: Online access Note: Free registration is required to access this paper. List(s) this item appears in: Covid-19: health and social care recovery in England [January 2023]
| Item type | Current library | Collection | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Web publication | The King's Fund Library Online resource | Web publications and sites | Web publications (Browse shelf(Opens below)) | Not for loan |
The pandemic response in the UK has now moved on to ‘phase 3’, setting out a gradual return to pre-Covid NHS service levels. The NHS is drawing up a ‘roadmap’ to recovery, and likewise, industry is beginning to look to the future to see where it fits in. This white paper looks at the next stages in the recovery for the NHS, and explores the vital role industry has in supporting the health service. It covers three major areas: the NHS Reset initiative and its attendant policies; the status and aims of the various NHS stakeholders tasked with taking the service through the next phase; and the issues surrounding the recovery from the point of view of the life science industries.
There are no comments on this title.